Summer 2026 - Translational Bioinformatics Internship at Bristol-Myers Squibb

Winter Garden, Florida, United States

Bristol-Myers Squibb Logo
Not SpecifiedCompensation
InternshipExperience Level
InternshipJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

  • Currently enrolled in a PhD program in bioinformatics, computational biology, biostatistics, or a related quantitative field
  • Proficiency in at least one scripting language (R preferred)
  • Familiarity with data reproducibility best practices (e.g., Git/GitHub; containers/workflows are a plus)
  • Experience analyzing spatial transcriptomics data and/or building prediction models using omics data types
  • A strong foundation of cancer biology is a plus
  • Must be able to work full-time for the program duration (June – August 2026)
  • Excellent written and verbal communication skills
  • All candidates must be authorized to work in the US both at the time of hire and for the duration of their employment (no immigration or visa sponsorship available)

Responsibilities

  • Apply predictive modeling techniques to identify candidate biomarkers that improve identification of patients with STK11 or KEAP1 genetic variations
  • Utilize spatial transcriptomic data to characterize molecular features associated with STK11 and KEAP1 genetic alterations in NSCLC
  • Flexible deliverables: Project goals may be tailored to fit the intern's interests and skills (e.g., predictive modeling can be broadened to benchmark multiple methodologies, and molecular characterization may extend to multi-modal datasets)

Skills

Key technologies and capabilities for this role

BioinformaticsSpatial TranscriptomicsPredictive ModelingOmics DatasetsComputational ModelingBiomarkersTranscriptomicsMulti-Modal Data AnalysisNSCLCSTK11KEAP1

Questions & Answers

Common questions about this position

What are the key responsibilities of this internship?

The intern will apply predictive modeling to identify biomarkers for STK11 or KEAP1 genetic variations, utilize spatial transcriptomic data to characterize molecular features in NSCLC, and work on flexible deliverables tailored to their interests and skills.

What qualifications are required for this internship?

Candidates must be currently enrolled in a PhD program in bioinformatics, computational biology, biostatistics, or a related quantitative field, with proficiency in at least one scripting language (R preferred), familiarity with data reproducibility best practices, and experience analyzing spatial transcriptomics data and/or building prediction models using omics data.

What is the duration and timing of this internship?

The full-time internship will take place from June to August 2026.

What is the work environment like at Bristol Myers Squibb?

The environment is challenging, meaningful, and life-changing, with uniquely interesting work, opportunities to grow alongside high-achieving teams in a collaborative, cross-functional team in a dynamic R&D setting, and a focus on balance and flexibility.

What makes a strong candidate for this internship?

Strong candidates are PhD students in relevant quantitative fields with hands-on experience in spatial transcriptomics or omics prediction models, proficiency in R or scripting, data reproducibility practices like Git, plus a foundation in cancer biology, excellent communication skills, and US work authorization.

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI